AstraZeneca's Lynparza cancer drug approved by Japan
Merck & Co. Inc.
$125.23
11:10 18/04/24
-0.11%
-$0.14
AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
AstraZeneca
10,828.00p
11:00 19/04/24
-0.79%
-86.00p
Dow Jones I.A.
37,775.38
04:30 15/10/20
n/a
n/a
FTSE 100
7,835.21
11:00 19/04/24
n/a
n/a
FTSE 350
4,309.22
11:00 19/04/24
n/a
n/a
FTSE All-Share
4,265.53
11:00 19/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
21,030.58
11:00 19/04/24
-0.48%
-102.19
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in The New England Journal of Medicine.